Dry Powder Inhalers are widely used for the treatment of local diseases, like Asthma and COPD and in recent years more and more applications for systemic delivery have been explored. This opens a wide potential, but also great challenges for developing Dry Powder Inhalers. There is a fine interplay between formulations, processes as well as devices to deliver drugs efficiently and consistently to the lungs. This is relevant for developing a classic low dose Asthma /COPD DPI, as well as for a new developments involving challenging powders used in higher doses. An integrated development approach of formulation and device is crucial to overcome the challenges, such as insufficient and inconsistent emitted dose and lung deposition across different flowrates.
During our presentation we want to outline the relevant aspects of developing a Dry Powder Inhaler ranging from formulation to device development. Showcasing different approaches to enable efficient delivery of traditional carrier-based formulations as well as more advanced formulations containing engineered particles. The first part focuses on low dose carrier-based formulations and how by adjusting formulation and device the aerodynamic performance can be tuned. The second part will showcase engineered particle platforms tailored to various API properties and their interaction with the device for an optimized performance and drug delivery.
This webinar will provide a clear picture of how device design and formulation development can be tuned to meet the different challenges in powder formulations.
Key Learning Objectives
- Challenges in DPI development
- High dose and low dose formulation tools
- High dose formulation platforms for efficient delivery
- Capsule-based DPI device development
Register